Clinic launch guide
Adding Exosomes to a Medical Spa
Reviewed by ExaVeyra Sciences editorial team · Updated 16 August 2026
Two routes are open to a licensed clinic today. The first is topical application to intact skin, described in terms of appearance rather than of treating a condition, which is how the great majority of aesthetic practices use this material. The second is research use, under the documentation and oversight that research carries. Both are well established, both are supplied routinely, and the practical question for a practice adding this line is which of the two it is actually operating in and whether its paperwork says so.
That question has a clean answer, and it turns on intended use rather than on the vial. This page sets out how the classification works, what each route asks of a practice, and what to require from a supplier before the first order arrives. It is written for a clinic that has decided to offer this and wants to build it properly.
What the material is
Exosomes are extracellular vesicles, which are small membrane-bound particles that cells release and that carry protein and nucleic acid cargo. A preparation is isolated from conditioned culture medium and then concentrated. What arrives at a clinic is a fraction of what the source cells secreted, not the source cells themselves, and that acellular character is the fact most of the regulatory analysis turns on.
The field has an agreed reporting standard for this. MISEV2023, published in the Journal of Extracellular Vesicles, is the third iteration of a consensus document setting out how vesicle preparations should be produced, separated, characterised and reported. It is the reference a serious supplier will already be working to, and it gives a purchasing clinic a neutral yardstick that does not depend on any vendor’s own claims.
How FDA classifies it
FDA set out its position in a public safety notification dated 6 December 2019. The operative sentence reads: "As a general matter, exosomes used to treat diseases and conditions in humans are regulated as drugs and biological products under the Public Health Service Act and the Federal Food Drug and Cosmetic Act and are subject to premarket review and approval requirements." The same notification states that there are currently no FDA-approved exosome products.
Two consequences follow that are worth stating plainly. A product marketed for a disease or condition sits in the drug and biologic frame, which means an approved biologics license application or an active investigational new drug application. A product supplied and used for appearance, on intact skin, is being used outside the frame that sentence describes. Neither of those is a loophole. They are two different intended uses with two different sets of obligations, and a practice picks one and documents it.
A related question comes up often enough to answer directly. Exosome preparations do not qualify as 361 human cells, tissues, and cellular and tissue-based products. The four criteria in 21 CFR 1271.10 are cumulative, and an isolated vesicle preparation fails more than one of them before the analysis gets difficult. Our reference on the 361 and 351 split works through each criterion with the regulation quoted in full.
What to require from a supplier
This is the part a clinic has real control over, and it is the part that separates a durable service line from a fragile one. Ask for the following in writing before the first order, and keep what comes back with the lot records.
- A lot-specific certificate of analysis, not a generic product specification sheet. The lot number on the COA should match the vial.
- Particle characterisation with the method named. Nanoparticle tracking analysis and microfluidic resistive pulse sensing give different numbers on the same sample, so a count without a method is not comparable to anything.
- Marker data. Tetraspanin panels such as CD9, CD63 and CD81 establish that vesicles are present and enriched. They do not establish potency, and a supplier who says otherwise is telling you something the assay cannot support.
- Sterility and endotoxin results for the lot, with the test method identified.
- Storage temperature, permitted excursion window, and what to do if a shipment arrives outside it.
- The manufacturing facility and its FDA registration status.
A supplier who can produce all six without a follow-up conversation is a supplier who has done this before. Build the receiving check into a standard operating procedure so it happens on every delivery rather than on the first one.
State law, and what it actually reaches
Practitioners frequently ask whether their state’s stem cell statute governs exosome material. In almost every state the answer is that it does not, and the reason is textual. Those statutes are written around cells and tissues. Florida’s provision at Fla. Stat. 458.3245 reaches "afterbirth placental perinatal stem cells, or human cells, tissues, or cellular or tissue-based products". Texas House Bill 810, codified at Tex. Health and Safety Code 1003.051, is built around adult stem cell treatment under an active clinical trial. An acellular vesicle preparation falls outside both descriptions.
Tennessee is the exception, and it is instructive. Public Chapter 1016, effective 1 July 2026, is the first US statute to name exosome-based regenerative products, and it does so by setting a supplier documentation standard covering particle counts, a lot-specific sterility report and a certificate of analysis. That is a documentation requirement rather than a product approval, and a practice that already runs the checklist above is most of the way to satisfying it.
What does vary meaningfully state to state is who may perform a given procedure, what supervision applies, and how the good-faith examination requirement is met. Those are practice-act questions rather than product questions, and our state guides cover them individually.
Documentation that carries the service line
Three documents do most of the work, and they need to agree with each other. Where they disagree, the record says one thing and the practice does another, which is the position worth avoiding.
| Document | What it establishes | The common gap |
|---|---|---|
| Written protocol | The intended use, the application route, and who performs each step | Describes an appearance service while the consent describes a condition |
| Informed consent | That the patient was told the product is not FDA-approved and what that means | Uses supplier marketing language rather than the practice’s own |
| Marketing copy | What the practice offers, in terms it can substantiate | Promises an outcome the protocol never claims |
A useful test: read the consent form and the website copy side by side and ask whether they describe the same service. If they do, the record is coherent. If the website is making a claim the protocol does not support, the website is the document to change.
Where to go next
If the open question is whether a topical application after a procedure changes the analysis, our companion page on topical application and microneedling works through the sequences in detail and quotes FDA’s position on what a cleared microneedling device is cleared to do. If the open question is how to study this material formally rather than offer it, our page on new indications and studies sets out the investigational pathway from the pre-IND meeting onward.
Sources
- FDA, Public Safety Notification on Exosome Products (6 December 2019) (accessed 16 August 2026)
- FDA, Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes (accessed 16 August 2026)
- FDA, Framework for the Regulation of Regenerative Medicine Products (accessed 16 August 2026)
- 21 CFR 1271.10, Are my HCT/Ps regulated solely under section 361 of the PHS Act? (accessed 16 August 2026)
- FDA, Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use (accessed 16 August 2026)
- FDA, MedWatch Adverse Event Reporting Program (accessed 16 August 2026)
Scientific literature
Each source carries the kind of study it was and, where the study enrolled people, how many. Study design decides what a result can establish, so it is stated rather than left to be inferred. Each line also says what that source is carrying on this page.
- Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. Journal of Extracellular Vesicles, 2024. doi:10.1002/jev2.12404 PMID:38326288Consensus statementSource 1 supports: The field’s agreed standard for how a vesicle preparation should be produced, characterised and reported. This is the yardstick a purchasing clinic can hold a supplier to without relying on the supplier’s own framing.
- Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles. Journal of Extracellular Vesicles, 2018. doi:10.1080/20013078.2018.1535750 PMID:30637094Consensus statementSource 2 supports: The prior iteration of the same standard, cited because supplier documentation written before 2024 was built against it rather than against MISEV2023.
- Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science, 2020. doi:10.1126/science.aau6977 PMID:32029601Narrative reviewSource 3 supports: General account of exosome biology, cited for what a vesicle is and how it is isolated rather than for any clinical effect.